ArticleCureus2026
Study of the Expression of Sex-Determining Region Y-box 2 (SOX2) in Squamous Cell Carcinoma of the Cervix.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer remains a major health concern among women, particularly in low-resource settings. Sex-determining region Y-box 2 (SOX2), a transcription factor involved in cellular self-renewal and differentiation, has been implicated in tumor progression and malignancy.
objectiveThis study aimed to evaluate and correlate the immunohistochemical expression of SOX2 across the spectrum of cervical squamous lesions and its association with clinicopathological parameters.
methodsThis cross-sectional observational study was conducted at Gandhi Medical College and Associated Hospitals, Bhopal, between May 2023 and October 2024. Eighty cervical specimens, including 63 biopsies and 17 hysterectomy samples, were classified as normal cervical epithelium (n = 20), cervical intraepithelial neoplasia (n = 20), and squamous cell carcinoma (SCC) (n = 40). SOX2 expression was evaluated by immunohistochemistry using a semiquantitative H-score based on staining intensity and percentage positivity. Statistical significance was assessed using the chi-square test with p < 0.05.
resultsSOX2 expression showed a significant progressive increase from normal cervical epithelium to malignant lesions (p = 0.0001). A higher proportion of SOX2-positive cases was observed in SCC cases (55%) than in premalignant (30%) and normal (0%) cases. A significant (p = 0.01) association was found between SOX2 expression and age groups and menopausal status (p = 0.01). No significant association was reported with SCC differentiation (p = 0.99) or International Federation of Gynecology and Obstetrics staging (p = 0.60).
conclusionSOX2 expression increases significantly with disease progression from normal epithelium to invasive carcinoma, suggesting its potential role as a biomarker for malignant transformation in cervical lesions. Further large-scale studies are required to establish its prognostic utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.